Contains Nonbinding Recommendations

Draft – Not for Implementation

Draft Guidance on Fludrocortisone Acetate

November 2025

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

In general, FDA's guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

Active Ingredient: Fludrocortisone acetate

Dosage Form: Tablet

Route: Oral

Strengths: 0.05 mg[1], 0.1 mg, and 0.2 mg[1]

Recommended Study: One in vivo bioequivalence study with pharmacokinetic endpoints

1. Type of study: Fasting
   Design: Single-dose, two-way crossover in vivo
   Strength: 0.2 mg
   Subjects: Healthy males and non-pregnant, non-lactating females
   Additional comments: Applicants may consider one of the following approaches which is appropriate at time of the study:
   - Conduct the study by testing one fludrocortisone acetate tablet (1 × 0.2 mg) of the test product compared to two fludrocortisone tablets (2 × 0.1 mg) of the reference standard (RS), when applicants use the reference listed drug (RLD) [2], NDA 010060, fludrocortisone acetate tablets, 0.1 mg as the RS.
   - Alternatively, applicants may conduct the study by testing one fludrocortisone acetate tablet (1 × 0.2 mg) of the test product compared to one fludrocortisone acetate tablet (1 × 0.2 mg) of the RS, when there is an approved petitioned abbreviated new drug application (ANDA) for fludrocortisone acetate tablets, 0.2 mg, which is designated as the RS.

[1] Strengths identified are the subject of an approved suitability petition (FDA-2024-P-4514).

[2] If the RLD is not available, refer to the most recent version of the guidance for industry *Referencing Approved Drug Products in ANDA Submissions.*

Analyte to measure: Fludrocortisone in plasma

Bioequivalence based on (90% CI): Fludrocortisone

Waiver request of in vivo testing: 0.05 mg, 0.1 mg strengths based on (i) an acceptable bioequivalence study on the 0.2 mg strength, (ii) acceptable in vitro dissolution testing of all the strengths, and (iii) proportional similarity of the formulations across all strengths

Dissolution test method and sampling times: The dissolution information for this drug product can be found in the FDA's Dissolution Methods database, http://www.accessdata.fda.gov/scripts/cder/dissolution. Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test product and RLD. Specifications will be determined upon review of the ANDA.

Document History: Recommended August 2009; Finalized October 2011; Revised October 2024, November 2025

Unique Agency Identifier: PSG_010060